Q2 EPS Forecast for Neurocrine Biosciences Raised by Analyst

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Research analysts at Wedbush lifted their Q2 2025 earnings per share (EPS) estimates for Neurocrine Biosciences in a report issued on Tuesday, May 6th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of $1.12 for the quarter, up from their previous forecast of $1.11. Wedbush currently has a "Outperform" rating on the stock. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.28 per share. Wedbush also issued estimates for Neurocrine Biosciences' Q3 2025 earnings at $1.34 EPS, Q4 2025 earnings at $1.38 EPS, FY2025 earnings at $3.92 EPS, FY2026 earnings at $5.77 EPS, FY2027 earnings at $8.90 EPS, FY2028 earnings at $10.49 EPS and FY2029 earnings at $13.78 EPS.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by ($0.62). The company had revenue of $572.60 million during the quarter, compared to analyst estimates of $587.06 million. Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. The firm's revenue was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.20 earnings per share.

Several other analysts have also recently issued reports on NBIX. Piper Sandler reiterated an "overweight" rating and issued a $154.00 price objective (down from $160.00) on shares of Neurocrine Biosciences in a research note on Tuesday, May 6th. Canaccord Genuity Group increased their price objective on Neurocrine Biosciences from $158.00 to $160.00 and gave the company a "buy" rating in a research note on Tuesday, May 6th. William Blair reiterated an "outperform" rating on shares of Neurocrine Biosciences in a research note on Friday, February 7th. BMO Capital Markets raised their price target on Neurocrine Biosciences from $96.00 to $115.00 and gave the company a "market perform" rating in a research note on Tuesday, May 6th. Finally, Evercore ISI cut their price target on Neurocrine Biosciences from $190.00 to $185.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. Three equities research analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company. Based on data from MarketBeat.com, Neurocrine Biosciences currently has an average rating of "Moderate Buy" and a consensus price target of $162.00.

Neurocrine Biosciences Price Performance

Shares of NASDAQ NBIX traded down $1.81 during mid-day trading on Friday, hitting $115.71. The company had a trading volume of 1,319,681 shares, compared to its average volume of 1,115,471. The company has a market capitalization of $11.45 billion, a PE ratio of 35.17, a price-to-earnings-growth ratio of 0.77 and a beta of 0.26. Neurocrine Biosciences has a 1-year low of $84.23 and a 1-year high of $157.98. The business's 50-day simple moving average is $106.23 and its 200 day simple moving average is $121.89.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of hedge funds have recently added to or reduced their stakes in the company. OneDigital Investment Advisors LLC lifted its position in Neurocrine Biosciences by 2.1% in the fourth quarter. OneDigital Investment Advisors LLC now owns 4,215 shares of the company's stock valued at $575,000 after purchasing an additional 87 shares during the period. HighPoint Advisor Group LLC lifted its position in Neurocrine Biosciences by 4.1% in the fourth quarter. HighPoint Advisor Group LLC now owns 2,446 shares of the company's stock valued at $334,000 after purchasing an additional 96 shares during the period. Huntington National Bank lifted its position in Neurocrine Biosciences by 73.5% in the fourth quarter. Huntington National Bank now owns 229 shares of the company's stock valued at $31,000 after purchasing an additional 97 shares during the period. Louisiana State Employees Retirement System lifted its position in Neurocrine Biosciences by 0.4% in the fourth quarter. Louisiana State Employees Retirement System now owns 28,100 shares of the company's stock valued at $3,836,000 after purchasing an additional 100 shares during the period. Finally, Utah Retirement Systems lifted its position in Neurocrine Biosciences by 0.6% in the fourth quarter. Utah Retirement Systems now owns 16,583 shares of the company's stock valued at $2,264,000 after purchasing an additional 100 shares during the period. Institutional investors and hedge funds own 92.59% of the company's stock.

Insider Buying and Selling

In related news, Director William H. Rastetter sold 30,000 shares of the firm's stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $110.20, for a total transaction of $3,306,000.00. Following the transaction, the director now owns 37,491 shares of the company's stock, valued at $4,131,508.20. This trade represents a 44.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Matt Abernethy sold 2,558 shares of the firm's stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $116.86, for a total value of $298,927.88. Following the transaction, the chief financial officer now directly owns 34,775 shares in the company, valued at approximately $4,063,806.50. This represents a 6.85% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 43,907 shares of company stock valued at $4,935,982 over the last quarter. 4.80% of the stock is currently owned by insiders.

Neurocrine Biosciences announced that its Board of Directors has approved a share buyback plan on Friday, February 21st that permits the company to repurchase $500.00 million in shares. This repurchase authorization permits the company to reacquire up to 4.2% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's leadership believes its shares are undervalued.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.